MétaCan
Menu
Back to cohort
Record W3041032524 · doi:10.1007/s00198-020-05497-8

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?

2020· review· en· W3041032524 on OpenAlexaff
Serge Rozenberg, Nasser M. Al‐Daghri, Mylène Aubertin‐Leheudre, Maria Luisa Brandi, Antonio Cano, Peter Collins, Cyrus Cooper, Andrea R. Genazzani, Tim Hillard, John А. Kanis, Jean‐Marc Kaufman, Ιrene Lambrinoudaki, Andrea Laslop, Eugène McCloskey, Santiago Palacios, Daniel Prieto‐Alhambra, Jean‐Yves Reginster, René Rizzoli, Giuseppe Rosano, Florence Trémollières, Nicholas C. Harvey

Bibliographic record

VenueOsteoporosis International · 2020
Typereview
Languageen
FieldMedicine
TopicMenopause: Health Impacts and Treatments
Canadian institutionsUniversité du Québec à Montréal
FundersVersus ArthritisMedical Research CouncilNational Institute for Health and Care Research
KeywordsMedicineOsteoporosisMenopauseContext (archaeology)Hormone therapyProgestogenConcomitantAdverse effectIntensive care medicineStroke (engine)GynecologyPhysical therapyInternal medicineBreast cancerEstrogenCancer

Abstract

fetched live from OpenAlex

We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal health and prevention of future fractures in recently menopausal women. Despite controversy over associated side effects, which has limited its use in recent decades, the potential role for MHT soon after menopause in the management of postmenopausal osteoporosis is increasingly recognized. We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovascular events, timing of MHT use. Overall, the benefit-risk profile supports MHT treatment in women who have recently (< 10 years) become menopausal, who have menopausal symptoms and who are less than 60 years old, with a low baseline risk for adverse events. MHT should be considered as an option for the maintenance of skeletal health in women, specifically as an additional benefit in the context of treatment of menopausal symptoms, when commenced at the menopause, or shortly thereafter, in the context of a personalized benefit-risk evaluation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.978
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.064
GPT teacher head0.377
Teacher spread0.313 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations148
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueOsteoporosis InternationalSame topicMenopause: Health Impacts and TreatmentsFrench-language works237,207